58550-84-8

Basic information

• Product Name: N-(phenylsulphonyl)-3-methylindole
• Synonyms: N-(phenylsulphonyl)-3-methylindole
• CAS NO: 58550-84-8
• Molecular Formula: C₁₅H₁₃NO₂S
• Molecular Weight: 271
• Mol File: 58550-84-8.mol
• Article Data: 20

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(phenylsulphonyl)-3-methylindole(CAS DataBase Reference)
• NIST Chemistry Reference: N-(phenylsulphonyl)-3-methylindole(58550-84-8)
• EPA Substance Registry System: N-(phenylsulphonyl)-3-methylindole(58550-84-8)

Safety Data

• Hazardous Substances Data: 58550-84-8(Hazardous Substances Data)

Upstream product

• 83-34-1 3-Methylindole 
• 98-09-9 benzenesulfonyl chloride 
• 80360-20-9 1-(phenylsulfonyl)indole-3-carbaldehyde 
• 80360-13-0 3-lithio-1-(phenylsulfonyl)indole 
• 74-88-4 methyl iodide 
• 193686-88-3 1,2-bis(phenylsulfonyl)-1H-indole 
• 80360-22-1 1-phenylsulfonyl-2-(phenylthio)-1H-indole 
• 120-72-9 indole 
• 26340-47-6 3-Iodo-1H-indole 
• 80360-14-1 3-iodo-1-phenylsulfonyl-1H-indole 
• 114996-64-4 3-methylidene-1-(phenylsulfonyl)indoline 
• 100-63-0 phenylhydrazine 
• 26304-51-8 ethyl 3-methyl-indole-2-carboxylate 

Downstream Products

• 79253-75-1 2-Hydroxy-2-(3-methyl-1H-indol-2-yl)-propionic acid methyl ester 
• 79253-78-4 3-Methyl-1,1-dioxo-1,3-dihydro-1λ⁶-benzo[c][1,2]oxathiole-3-carboxylic acid methyl ester 
• 119907-79-8 1-Benzenesulfonyl-2-methanesulfinyl-3-methyl-1H-indole 
• 131131-37-8 2-(1-Benzenesulfonyl-3-methyl-1H-indol-2-yl)-1,1,1-trifluoro-propan-2-ol 
• 110396-65-1 3-methyl-1-(phenylsulfonyl)-1H-indole-2-carbaldehyde 
• 58550-78-0 N-benzenesulfonyl-3-(bromomethyl)indole 
• 127680-65-3 1-Benzenesulfonyl-3-methyl-2,3-dihydro-1H-indole 
• 77507-64-3 (1-Benzenesulfonyl-3-methyl-1H-indol-2-yl)-pyridin-4-yl-methanone 
• 143774-66-7 <3-methyl-1-(phenylsulfonyl)indol-2-yl>phenylmethanol 
• 143774-62-3 1-<3-methyl-1-(phenylsulfonyl)indol-2-yl>ethanol 
• 77507-53-0 (3-methyl-1-(phenylsulfonyl)-1H-indol-2-yl)(phenyl)methanone 
• 108665-98-1 1-(phenylsulfonyl)-2-chloroskatole 
• 77507-54-1 (1-phenylsulfonyl-3-methyl-1H-indol-2-yl)(4-chlorophenyl)methanone 
• 135037-10-4 2-<3-methyl-1-(phenylsulfonyl)-1H-indol-2-yl>ethanol 

Relevant articles and documents

Construction of pyrrole- and indole-fused CF3-piperazine derivatives

A series of pyrrole- and indole-fused trifluoromethyl-functionalized piperazine derivatives were constructed in moderate to good yields with excellent chemoselectivities via a Pictet-Spengler reaction under mild and operationally simple conditions. The synthetic utility of this protocol was further extended by the facile preparation of indole-fused CF3-1,4-diazocane and enantioenriched CF3-piperazines via a vinylogous Pictet-Spengler reaction and an asymmetric Pictet-Spengler reaction, respectively.

Development of indole sulfonamides as cannabinoid receptor negative allosteric modulators

Existing CB1 negative allosteric modulators (NAMs) fall into a limited range of structural classes. In spite of the theoretical potential of CB1 NAMs, published in vivo studies have generally not been able to demonstrate the expected therapeutically-relevant CB1-mediated effects. Thus, a greater range of molecular tools are required to allow definitive elucidation of the effects of CB1 allosteric modulation. In this study, we show a novel series of indole sulfonamides. Compounds 5e and 6c (ABD1075) had potencies of 4 and 3?nM respectively, and showed good oral exposure and CNS penetration, making them highly versatile tools for investigating the therapeutic potential of allosteric modulation of the cannabinoid system.

N- (ARYLALKYL) - 1H- INDOLE- 2 - SULFONIC ACID AMIDE COMPOUNDS AND THEIR THERAPEUTIC USE AS CANNABINOID ALLOSTERIC MODULATORS

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain /V-(arylalkyl)-1 H-indole- 2-sulfonic acid amide compounds that, inter alia, inhibit cannabinoid receptor signalling. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit cannabinoid receptor signalling; to treat disorders that are ameliorated by the inhibition of cannabinoid receptor signalling; to treat metabolic syndrome, type-2 diabetes, dyslipidaemia, obesity, eating disorders, cardiovascular diseases and disorders, and other conditions as described herein.